Peter Thompson Sells 115,844 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 115,844 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock traded up $2.35 during midday trading on Thursday, reaching $43.99. The stock had a trading volume of 328,677 shares, compared to its average volume of 364,115. The stock has a market capitalization of $1.99 billion, a P/E ratio of -22.79 and a beta of 1.33. The firm’s fifty day simple moving average is $39.79 and its 200-day simple moving average is $39.49. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, sell-side analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Stifel Nicolaus increased their price objective on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. JonesTrading raised their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Wedbush began coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $53.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SION. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics in the 4th quarter valued at $26,290,000. Vanguard Group Inc. boosted its position in Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp boosted its position in Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the period. Jennison Associates LLC increased its holdings in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares during the last quarter. Finally, Viking Global Investors LP increased its holdings in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.